Andrew M Brunner

13PUBLICATIONS
81CO-AUTHORS
Innate immunityAdolescent healthApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Medical mycologyGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Apr 09, 2026
Sialylated CD43 forms a glyco-immune barrier that restrains antileukemic immunity.

Jooho Chung, Mounica Vallurupalli, Sarah Noel

|Jan 04, 2024
Treatment completion, asparaginase completion, and oncologic outcomes among children, adolescents and young adults with acute lymphoblastic leukemia treated with DFCI Consortium Protocols.

Yannis K Valtis, Yael Flamand, Shai Shimony

|Nov 23, 2023
Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes.

Andrew M Brunner, Jordi Esteve, Kimmo Porkka

|Apr 04, 2023
Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia.

Amir T Fathi, Haesook T Kim, Robert J Soiffer

|Dec 14, 2022
Management of patients with lower-risk myelodysplastic syndromes.

Andrew M Brunner, Heather A Leitch, Arjan A van de Loosdrecht

|Feb 10, 2022
Historical expectations with DNA methyltransferase inhibitor monotherapy in MDS: when is combination therapy truly "promising"?

Andrew M Brunner, Geoffrey Fell, David P Steensma

Pageof 3

Frequent Collaborators

2 joint publications

Daniel J DeAngelo

2 joint publications

David P Steensma

2 joint publications

Areej El-Jawahri

2 joint publications

Guillermo Garcia-Manero